Open AccessResponse of Homocysteine, Cystathionine, and Methylmalonic Acid to Vitamin Treatment in Dialysis Patients
Author(s) -
Rima Obeid,
Martin K. Kuhlmann,
Hans Köhler,
Wolfgang Herrmann
Publication year - 2004
Publication title -
clinical chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.705
H-Index - 218
eISSN - 1530-8561
pISSN - 0009-9147
DOI - 10.1373/clinchem.2004.041210
Subject(s) - hyperhomocysteinemia , homocysteine , methylmalonic acid , medicine , cystathionine beta synthase , dialysis , hemodialysis , endocrinology , creatinine , gastroenterology , chemistry , biochemistry , methionine , amino acid
Hyperhomocysteinemia is observed in >80% of hemodialysis patients and is considered a risk factor for cardiovascular disease. Vitamin treatment lowers total homocysteine (tHcy) concentrations in plasma and may therefore reduce the associated risk. Current treatment strategies have not achieved normalization of tHcy in the majority of dialysis patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom